Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
©2023 The Authors; Published by the American Association for Cancer Research..
Mutations in the tumor suppressor TP53 cause cancer and impart poor chemotherapeutic responses, reportedly through loss-of-function, dominant-negative effects and gain-of-function (GOF) activities. The relative contributions of these attributes is unknown. We found that removal of 12 different TP53 mutants with reported GOFs by CRISPR/Cas9 did not impact proliferation and response to chemotherapeutics of 15 human cancer cell lines and colon cancer-derived organoids in culture. Moreover, removal of mutant TP53/TRP53 did not impair growth or metastasis of human cancers in immune-deficient mice or growth of murine cancers in immune-competent mice. DepMap mining revealed that removal of 158 different TP53 mutants had no impact on the growth of 391 human cancer cell lines. In contrast, CRISPR-mediated restoration of wild-type TP53 extinguished the growth of human cancer cells in vitro. These findings demonstrate that LOF but not GOF effects of mutant TP53/TRP53 are critical to sustain expansion of many tumor types.
SIGNIFICANCE: This study provides evidence that removal of mutant TP53, thereby deleting its reported GOF activities, does not impact the survival, proliferation, metastasis, or chemotherapy responses of cancer cells. Thus, approaches that abrogate expression of mutant TP53 or target its reported GOF activities are unlikely to exert therapeutic impact in cancer. See related commentary by Lane, p. 211 . This article is featured in Selected Articles from This Issue, p. 201.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancer discovery - 14(2024), 2 vom: 08. Feb., Seite 362-379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Zilu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-23-0402 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363700064 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363700064 | ||
| 003 | DE-627 | ||
| 005 | 20240210232807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0402 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363700064 | ||
| 035 | |a (NLM)37877779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Zilu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a Mutations in the tumor suppressor TP53 cause cancer and impart poor chemotherapeutic responses, reportedly through loss-of-function, dominant-negative effects and gain-of-function (GOF) activities. The relative contributions of these attributes is unknown. We found that removal of 12 different TP53 mutants with reported GOFs by CRISPR/Cas9 did not impact proliferation and response to chemotherapeutics of 15 human cancer cell lines and colon cancer-derived organoids in culture. Moreover, removal of mutant TP53/TRP53 did not impair growth or metastasis of human cancers in immune-deficient mice or growth of murine cancers in immune-competent mice. DepMap mining revealed that removal of 158 different TP53 mutants had no impact on the growth of 391 human cancer cell lines. In contrast, CRISPR-mediated restoration of wild-type TP53 extinguished the growth of human cancer cells in vitro. These findings demonstrate that LOF but not GOF effects of mutant TP53/TRP53 are critical to sustain expansion of many tumor types | ||
| 520 | |a SIGNIFICANCE: This study provides evidence that removal of mutant TP53, thereby deleting its reported GOF activities, does not impact the survival, proliferation, metastasis, or chemotherapy responses of cancer cells. Thus, approaches that abrogate expression of mutant TP53 or target its reported GOF activities are unlikely to exert therapeutic impact in cancer. See related commentary by Lane, p. 211 . This article is featured in Selected Articles from This Issue, p. 201 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 700 | 1 | |a Burigotto, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Ghetti, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Vaillant, François |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Capaldo, Bianca D |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hirokawa, Yumiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tai, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson, Daniel S |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Allan Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Lieschke, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Diepstraten, Sarah T |e verfasserin |4 aut | |
| 700 | 1 | |a Kaloni, Deeksha |e verfasserin |4 aut | |
| 700 | 1 | |a Riffkin, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, David C S |e verfasserin |4 aut | |
| 700 | 1 | |a Li Wai Suen, Connie S N |e verfasserin |4 aut | |
| 700 | 1 | |a Garnham, Alexandra L |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Visvader, Jane E |e verfasserin |4 aut | |
| 700 | 1 | |a Sieber, Oliver M |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Marco J |e verfasserin |4 aut | |
| 700 | 1 | |a Fava, Luca L |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Gemma L |e verfasserin |4 aut | |
| 700 | 1 | |a Strasser, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 14(2024), 2 vom: 08. Feb., Seite 362-379 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:08 |g month:02 |g pages:362-379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0402 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 08 |c 02 |h 362-379 | ||